Prophylaxis of cytomegalovirus disease in high-risk patients.

被引：2
|
作者：
Scholz, M
Cinatl, J
Doerr, W
机构：
[1] Johann Wolfgang Goethe-Universität,Institut für Medizinische Virologie
来源：
INFECTION | 1997年 / 25卷 / 05期
关键词：
D O I：
10.1007/BF01720395
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
CMV disease is an important peristent factor for enhanced morbidity and mortality in immunocompromised patients. In high-risk patients the prevention of primary infection or reactivation of latent infection is endeavoured by means of various antiviral strategies. However, the prevention of CMV disease by immunomodulators appears to be a hopeful additional tool for the treatment of immunocompromised patients and ought to be further investigated.
引用
收藏
页码：269 / 273
页数：5
相关论文
共 50 条
  • [31] Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Brady, R. L.
    Green, K.
    Frei, C.
    Maxwell, P.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (02) : 106 - 111
  • [32] Effect of PSA on equal treatment of high-risk patients.
    Ferenczi, Basil
    Frankel, Jason
    Jung, Nathan
    Porter, Christopher
    Flores, John Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Combination immunotherapy for high-risk and advanced melanoma patients.
    Riker, A. I.
    Vahanian, N. N.
    Link, C. J.
    Tennant, L.
    Ramsey, W. J.
    Rossi, G. R.
    Alsfeld, L. C.
    Davila, E.
    Harrison, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Effect of ramipril on cardiovascular events in high-risk patients.
    O'Rourke, MF
    Nichols, WW
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (01): : 64 - 65
  • [35] Development of high-risk prophylaxis
    不详
    ORTHOPADE, 2000, 29 (01): : B2 - B2
  • [36] Prophylaxis of cytomegalovirus disease in transplant patients
    Uknis, ME
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 : S3 - S6
  • [37] Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients
    Cervera, C.
    Pineda, M.
    Linares, L.
    Marcos, M. A.
    Esteva, C.
    Anton, A.
    Cofan, F.
    Ricart, M. J.
    Navasa, M.
    Perez-Villa, F.
    Pumarola, T.
    Moreno, A.
    TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2228 - 2230
  • [38] Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients
    Imlay, Hannah
    Dumitriu Carcoana, Allison O.
    Fisher, Cynthia E.
    Wong, Beatrice
    Rakita, Robert M.
    Fishbein, Daniel P.
    Limaye, Ajit P.
    TRANSPLANT INFECTIOUS DISEASE, 2020, 22 (03)
  • [39] A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients
    Nafar, M
    Pezeshki, ML
    Farrokhi, F
    Einollahi, B
    Pour-Reza-Gholi, F
    Firouzan, A
    Farhangi, S
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (07) : 3053 - 3055
  • [40] Prophylaxis of cytomegalovirus (CMV) disease in high-risk renal transplant recipients. A randomized comparison of valacyclovir with oral ganciclovir
    不详
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (02): : 98 - 98
12345